| Ytd | -35.06% | |
| 1y | -84.16% |
| Open | 0.25 | Prev Close | 0.25 | Low | 0.25 | High | 0.29 | Mkt Cap | 43.24M |
| Vol | 1.19M | Avg Vol | 4.34M | EPS | -0.20 | P/E | N/A | Forward P/E | -113.00 |
| Beta | 0.36 | Short Ratio | 8.10 | Inst. Own | 70.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 0.31 | 200-d Avg | 0.61 | 1yr Est | 7.04 |
MREO News
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday'
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the ana
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investig
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's
Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD,
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering f
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the ana
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "C
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Mereo BioPh
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
NEW YORK--(BUSINESS WIRE)---- $MREO #ClassAction--Faruqi & Faruqi, LLP, a leading national securitie
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action law
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
NEW YORK, April 5, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds p
New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors abou
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the ana
BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and mainta
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
Ultragenyx stock closed 42% lower on Monday as from Phase 3 studies for setrusumab in OI revealed no
Jefferies analyst Maury Raycroft downgrades Mereo BioPharma Group (NASDAQ:MREO) from Buy to Hold
U.S. stocks fell on Monday, with Nasdaq down 100 points. Nvidia Corp. and Mereo BioPharma Group plc
BTIG analyst Julian Harrison maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers
LifeSci Capital analyst Cory Jubinville downgrades Mereo BioPharma Group (NASDAQ:MREO) from Outpe
